Medicus Pharma Ltd. (MDCX)

Medicus Pharma advances pipeline during Q2 with key milestones

Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

SK Hynix backed by Wedbush as memory undersupply persists

Medicus Pharma CMO to lead Antev's Teverelix clinical programme

Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom

Medicus Pharma targets Gorlin Syndrome with SkinJect - ICYMI

Medicus Pharma targets Gorlin Syndrome with SkinJect - ICYMI

Medicus Pharma receives UAE authorization for Phase 2a endometriosis study of Teverelix

Roblox shares plummet on revenue miss, withdrawn guidance

Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis

Reddit shares slump after management warns of search traffic volatility despite strong earnings beat

Medicus Pharma receives UAE authorization for Phase 2a endometriosis study of Teverelix

Honeywell upgraded by Bank of America on stronger order trends

Medicus Pharma receives FDA clearance to begin registrational SkinJect study for Gorlin syndrome

Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome

Nvidia in talks to back OpenAI data center financing with $250B guarantee, WSJ reports

Medicus Pharma CEO details Teverelix progress – ICYMI

Medicus Pharma CEO details Teverelix progress – ICYMI

Medicus Pharma advances Teverelix Phase 2 study after FDA feedback, IRB approval

Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention